A recent study reminds us of the importance of cleaning our equipment. While healthcare has made a big push on cleaning hands, offering hand sanitizing gels in our hallways for workers and guests, insisting on routine hand washing between patients, and...(read more)
GlaxoSmithKline and Theravance, Inc. today announced that the US Food and Drug Administration (FDA) has approved ANORO ELLIPTA as a combination anticholinergic/long-acting beta2-adrenergic agonist (LABA) indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. Anoro Ellipta is not indicated for the relief of acute bronchospasm or for the treatment of asthm
In news that will probably shock no respiratory therapist anywhere, a new study shows that vanishingly few adults properly administer inhalers to asthmatic children in their care. It's unclear why there's such a problem with education, but this appears to be another area where failure to utilize respiratory therapists is leading to lower quality care.